Semglee

Conditions Treated

Semglee is an injectable prescription medicine used to lower blood sugar levels in patients with diabetes mellitus. It is indicated for:

• Type 1 Diabetes: Used in adults and pediatric patients.
• Type 2 Diabetes: Used in adults.

This medication is a long-acting, or basal, insulin. It works by replacing the insulin that the body would normally produce and by helping move sugar from the blood into other body tissues to be used for energy. It also helps prevent the liver from producing more sugar.

Semglee is designed to provide a consistent level of insulin for about 24 hours. It is typically used once daily and may be used in combination with other diabetes medications or shorter-acting insulins as part of a complete treatment plan that includes diet and exercise.

Mechanism of Action

Semglee (insulin glargine-yfgn) is a long-acting basal insulin designed to regulate glucose metabolism. It works by mimicking the steady release of insulin normally provided by a healthy pancreas. The medication lowers blood sugar through several primary actions:

• Glucose Absorption: It signals cells throughout the body, particularly in skeletal muscle and fat, to absorb sugar from the bloodstream so it can be used for energy.
• Liver Regulation: It inhibits the liver from producing and releasing excess sugar into the blood.
• Metabolic Balance: It helps the body process proteins and fats while preventing the breakdown of stored fat and protein into sugar.

Steady Release Profile

The medication is engineered to have low solubility at a neutral pH. When it is injected into the fatty tissue under the skin, the acidic solution is neutralized by the body. This process causes the insulin to form micro-precipitates, which are tiny clusters that dissolve slowly over time.

This slow dissolution results in a gradual, consistent release of insulin into the bloodstream. Unlike rapid-acting insulins, Semglee provides a relatively constant concentration of medication for approximately 24 hours. Because it lacks a pronounced peak in activity, it helps maintain stable blood sugar levels between meals and during sleep.

Common Side Effects

The most frequent side effect of Semglee is hypoglycemia (low blood sugar). Other common side effects may include:

• Redness, swelling, itching, or pain at the injection site.
• Changes in skin texture at the injection site, such as thickening or pits (lipodystrophy).
• Weight gain.
• Swelling in the hands, ankles, or feet (edema).
• Symptoms of a cold or upper respiratory infection.

Serious Side Effects

Some side effects can be serious and require immediate medical attention. Contact a healthcare provider right away if you experience:

• Severe hypoglycemia: Symptoms include extreme confusion, dizziness, blurred vision, slurred speech, or loss of consciousness.
• Severe allergic reactions: Signs may include a whole-body rash, difficulty breathing, fast heartbeat, sweating, or swelling of the face, tongue, or throat.
• Low potassium (hypokalemia): Symptoms may include muscle cramps, abnormal heart rhythms, or extreme weakness.
• Heart failure: New or worsening shortness of breath, sudden weight gain, or swelling in the legs or ankles, especially if taken with certain other diabetes medications like thiazolidinediones (TZDs).

Hypoglycemia

Hypoglycemia, or low blood sugar, is the most common side effect of insulin therapy and can be life-threatening. Severe hypoglycemia can cause seizures, loss of consciousness, or death. Monitoring blood glucose is essential for all patients using insulin, as the timing of hypoglycemia depends on the insulin's action profile.

Never Share Pens or Needles

Semglee prefilled pens must never be shared between patients, even if the needle is changed. Sharing pens or needles increases the risk of spreading bloodborne pathogens, such as hepatitis or HIV.

Hypersensitivity Reactions

Severe, life-threatening allergic reactions, including anaphylaxis, can occur with insulin products. Symptoms may include a whole-body rash, shortness of breath, wheezing, fast pulse, or sweating. If a serious reaction occurs, the medication should be discontinued and medical help sought immediately.

Hypokalemia

All insulin products, including Semglee, cause a shift in potassium from the blood into the cells, which may lead to hypokalemia (low potassium). If left untreated, this can cause respiratory paralysis, heart rhythm irregularities, and death. Monitoring is especially important for patients at risk, such as those using potassium-lowering medications.

Heart Failure Risk

When used in combination with thiazolidinediones (TZDs), Semglee may cause fluid retention and heart failure. Patients should be monitored for signs of heart failure, such as shortness of breath, swelling of the ankles or feet, and sudden weight gain. If heart failure develops, the TZD may need to be reduced or discontinued.

Medication Errors

Accidental mix-ups between Semglee and other insulins have been reported. To avoid medication errors, the label must be checked before every injection to confirm the correct insulin is being used. Patients should also be aware that changes in insulin strength, manufacturer, or type may require a change in dosage under medical supervision.

Pregnancy

Research on insulin glargine, the active ingredient in Semglee, has not identified a clear link between its use and an increased risk of major birth defects, miscarriage, or other adverse outcomes for the parent or the baby. Maintaining stable blood sugar levels is critical during pregnancy, as poorly controlled diabetes can increase the risk of complications such as pre-eclampsia, premature birth, or high birth weight.

Breastfeeding

It is generally considered safe to use Semglee while breastfeeding. While it is not known exactly how much insulin glargine passes into human milk, insulin is a natural substance that is typically broken down in the infant's digestive tract. It is unlikely to cause harm to a nursing child.

Management and Monitoring

Insulin needs often change significantly during pregnancy and the postpartum period. Healthcare providers typically monitor blood sugar levels closely to adjust dosages as needed. If you are pregnant, planning to become pregnant, or breastfeeding, discuss your treatment plan with your doctor to ensure the best outcomes.

Available Forms

Semglee is an injectable solution for subcutaneous administration. It is available in the following formats:

• Multi-dose vial: A glass vial designed for use with insulin syringes.
• Prefilled pen: A disposable, single-patient-use injector pen.

The medication is a clear, colorless solution. It should not be used if the liquid is cloudy, colored, or contains visible particles.

FDA Approval and Interchangeability

Semglee (insulin glargine-yfgn) is an FDA-approved long-acting human insulin analog. It is significant for being the first biosimilar insulin product to receive an interchangeable designation from the FDA. This status allows the medication to be substituted for its reference product, Lantus, at the pharmacy level without requiring a new prescription from the healthcare provider, depending on specific state pharmacy laws.

Approved Indications

The FDA has approved Semglee to improve glycemic control in the following populations:

• Adults and pediatric patients with type 1 diabetes mellitus.
• Adults with type 2 diabetes mellitus.

Semglee is not indicated for the treatment of diabetic ketoacidosis.

Regulatory Safety Information

There are currently no boxed warnings or Risk Evaluation and Mitigation Strategies (REMS) required for Semglee. Regulatory labeling includes standard safety warnings for insulin products, focusing on the risk of hypoglycemia (low blood sugar) and hypersensitivity reactions. As an interchangeable biosimilar, the FDA has determined that Semglee meets rigorous standards for safety, purity, and potency, and is expected to produce the same clinical result as the reference product in any given patient.

Cost and Availability

Semglee was approved by the FDA as the first interchangeable biosimilar for Lantus (insulin glargine). Because it is interchangeable, pharmacists may be able to substitute Semglee for Lantus without a new prescription from a healthcare provider, depending on state laws. This interchangeability is intended to increase competition and lower the cost of insulin therapy.

Factors Influencing Price

The actual cost of Semglee can vary based on several factors, including:

• Insurance Coverage: Many insurance plans include Semglee on their formularies, but copays and out-of-pocket costs depend on the specific plan.
• Branded vs. Unbranded: The manufacturer produces both a branded version (Semglee) and an unbranded version (Insulin Glargine-yfgn). The unbranded version is often available at a lower list price.
• Pharmacy Choice: Prices may differ between retail pharmacies, mail-order services, and specialty pharmacies.
• Dosage and Quantity: The total cost will depend on the prescribed dose and whether the medication is purchased in vials or pre-filled pens.

Patients may be eligible for manufacturer savings programs or patient assistance programs to help reduce out-of-pocket expenses. It is recommended to check with insurance providers and local pharmacies for the most current pricing information.